DATE – Page 11 – Talk Bio

ASH 2024: Anito-cel Demonstrates Enhanced Response Rate and Consistent Safety in Phase II Update for Relapsed/Refractory Multiple Myeloma

6 months ago talkbio0Tagged 2024, anito-cel, Arcellx, Asymmetric Septal Hypertrophy, Phase II Update, Profiling (action), Rating (action), relapsed/refractory multiple myeloma, Response process, Safety

ASH 2024, Anito-cel, Arcellx, Relapsed/Refractory Multiple Myeloma, Phase II Update, Response Rate, Safety Profile

Healthcare M&A and IRA Price Negotiations: Key Trends to Watch Amidst Political Shifts

6 months ago talkbio0Tagged Acquisitions, Drug Industry, drug price, Healthcare M&A, Inflation, Ira (eukaryote), Mediation, Medicare, mergers, Negotiation Program, Prices, trends qualifier

Healthcare M&A, IRA Price Negotiations, Medicare Drug Price Negotiation Program, Inflation Reduction Act, Pharmaceutical Industry Trends, Mergers and Acquisitions Outlook 2024

Navigating JPM Week 2024: Insights and Opportunities in Biopharma

7 months ago talkbio0Tagged Biopharma, deal-making, Industry, Investments, IPOs, JPM, M&A, Network, regulatory, trends qualifier

JPM Week 2024, Biopharma, Industry Insights, Networking, Deal-making, Investment, M&A, IPOs, Regulatory Trends

Empowering Women in Life Sciences: 2024’s Trailblazers in Biopharma R&D

7 months ago talkbio0Tagged 2024, Biological Science Disciplines, Biopharma, Fiercest, Gender, Health care facility, innovation, R&D, Women

Women in Life Sciences, Biopharma R&D, 2024’s Fiercest Women, Gender Balance, Innovation in Healthcare

Pharmaceutical Giants Eli Lilly and Novo Nordisk Face Challenges Despite Strong Sales Growth

7 months ago talkbio0Tagged competition, Drug Industry, Eli, Eli Lilly, financial results, issues, Market, Nordisk, Obesity, Pricing, Q3 2024, Weight loss therapies

Eli Lilly, Novo Nordisk, Q3 2024 financial results, Obesity drugs, Weight loss therapies, Pharmaceutical industry challenges, Market competition, Supply pressures, Pricing issues

Gilead Sciences Surpasses Q3 Earnings and Sales Forecasts, Boosts Annual Outlook

7 months ago talkbio0Tagged Advice, annual, Biktarvy, earnings, Gilead Sciences, HIV, HIV Prevention, Lenacapavir, Veklury

Gilead Sciences, Q3 earnings, HIV drug sales, annual guidance, Biktarvy, Veklury, lenacapavir, HIV prevention

Gilead and Arcellx Present Promising CAR-T Therapy Data for Advanced Multiple Myeloma, Highlighting Safety and Efficacy Against Carvykti

7 months ago talkbio0Tagged 2024, Arcellx, Asymmetric Septal Hypertrophy, CAR-T, Carvykti, Effectiveness, Gilead, Multiple Myeloma, relapsed/refractory multiple myeloma, safety profile

Gilead, Arcellx, CAR-T therapy, multiple myeloma, anito-cel, Carvykti, ASH 2024, safety profile, efficacy, relapsed/refractory multiple myeloma

Pharma’s Future at Stake: Trump’s Victory and Its Implications for Drug Pricing Reform

7 months ago talkbio0Tagged 2024, Biopharma, Donald Trump, Drug Industry, Drug Pricing Reform, Inflation, Kamala Harris, Mediation, Medicare, presidential election, Prices

Donald Trump, Kamala Harris, 2024 Presidential Election, Drug Pricing Reform, Inflation Reduction Act, Medicare Price Negotiations, Pharmaceutical Industry, Biopharma.

Vertex Pharmaceuticals Surpasses Q3 Expectations, Boosts Annual Revenue Forecast on Strong Cystic Fibrosis Sales

7 months ago talkbio0Tagged Casgevy, Cystic Fibrosis, earnings, full-year, Genetic Therapy, revenue guidance, Suzetrigine, Trikafta sales, vanzacaftor triple, VX-548

Vertex Pharmaceuticals, Q3 2024 earnings, Cystic fibrosis treatments, Trikafta sales, Full-year revenue guidance, Genetic therapies, Vanzacaftor triple, Suzetrigine (VX-548), Casgevy

EU Regulators Schedule December 6 Decision on Novo Holdings’ Acquisition of Catalent

7 months ago talkbio0Tagged Acquisition, Catalent, deadline, December, December 6, EU, Holdings, Regulators (device)

EU regulators, Novo Holdings, Catalent, acquisition, antitrust review, December 6 deadline